Agendia to Deliver Robust Suite of Data Advancing Breast Cancer Care at ASCO 2022
Agendia, Inc., a commercial stage company focused on enabling optimized decision-making by providing physicians with next-generation diagnostic and information solutions that can be used to help improve outcomes for breast cancer patients worldwide, today announced it will present new data from ongoing clinical research evaluating its comprehensive genomic tests at the upcoming American Society of Clinical Oncology Annual Meeting (ASCO), taking place June 3-7, 2022 in Chicago, Illinois.
Data will highlight Agendia’s clinical focus on whole transcriptome analysis as well as breast cancer care for underserved populations, in addition to several sub-studies derived from the company’s FLEX Registry, the real-world, multicenter, prospective, observational breast cancer study. Two abstracts selected by ASCO for oral discussion will feature an investigation of the ImPrint genomic test, currently for research use only, from the I-SPY trial series and an analysis from FLEX of hormone receptor-positive breast cancer in Black women classified by BluePrint®.
The company believes the FLEX Registry’s approach to cancer research is accelerating impactful data generation, aimed at redefining cancer care. Its patient-centric design and national network of participating sites is backed by Agendia’s infrastructure, allowing its investigator-initiated sub-studies to produce important results that have the potential to drive science forward, like those being shared at ASCO 2022.
Following are details of the nine Agendia abstracts that have been accepted for poster discussion or poster sessions at the ASCO 2022 Annual Meeting:
Poster discussion sessions
- The ImPrint immune signature to identify patients with high-risk early breast cancer who may benefit from PD1 checkpoint inhibition in I-SPY2
Authors: Kuilman, MM., et al.
Presenter: Lorenza Mittempergher, PhD | Research and Development, Agendia NV
Session: Breast Cancer – Local/Regional/Adjuvant
Poster Discussion: Monday, June 6, 2022 | 1:15 PM-2:45 PM CDT
Abstract #: 514 - Whole transcriptomic analysis of HR+ breast cancer in Black women classified as basal-type by BluePrint
Authors: Reid, S., et al.
Presenter: Sonya A. Reid, MD, MPH | Vanderbilt University Medical Center
Session: Breast Cancer – Local/Regional/Adjuvant
Poster Discussion: Monday, June 6, 2022 | 1:15 PM-2:45 PM CDT
Abstract #: 517
Poster sessions - Whole transcriptome analysis of tumors with discordant oncotype and MammaPrint results in the FLEX trial
Authors: Socoteanu, M., et al.
Session: Breast Cancer – Local/Regional/Adjuvant
Session Date & Time: Monday, June 6, 2022 | 8:00 AM-11:00 AM CDT
Abstract #: 556 - Clinical implications for patients with discordant oncotype and MammaPrint results
Authors: Socoteanu, M., et al.
Session: Breast Cancer – Local/Regional/Adjuvant
Session Date & Time: Monday, June 6, 2022 | 8:00 AM-11:00 AM CDT
Abstract #: 560 - Investigation of a genomic signature for transcription factor MAF gene amplification and lack of bisphosphonate benefit in early breast cancer
Authors: Nasrazadani, A., et al.
Session: Breast Cancer – Local/Regional/Adjuvant
Session Date & Time: Monday, June 6, 2022 | 8:00 AM-11:00 AM CDT
Abstract #: 559 - Identification of transcriptional changes with MammaPrint and BluePrint in early-stage breast cancer after neoadjuvant chemotherapy
Authors: Chung, A., et al.
Session: Breast Cancer – Local/Regional/Adjuvant
Session Date & Time: Monday, June 6, 2022 | 8:00 AM-11:00 AM CDT
Abstract #: 585 - Distribution of breast cancer molecular subtypes within receptor classifications: Lessons from the I-SPY2 trial and FLEX Registry
Authors: Cha, J., et al.
Session: Breast Cancer – Local/Regional/Adjuvant
Session Date & Time: Monday, June 6, 2022 | 8:00 AM-11:00 AM CDT
Abstract #: 592 - FLEX, the 30,000 breast cancer transcriptome project: A platform for early breast cancer research using full-genome arrays paired with clinical data
Authors: Ma, C., et al.
Session: TBC
Session Date & Time: Monday, June 6, 2022 | 8:00 AM-11:00 AM CDT
Abstract #: TPS612 - Defining transcriptomic profiles of early-stage mucinous breast cancers: A FLEX sub study
Authors: Sivapiragasam, A., et al.
Session: Developmental Therapeutics – Molecularly Targeted Agents and Tumor Biology
Session Date & Time: Sunday, June 5, 2022 | 8:00 AM-11:00 AM CDT
Abstract #: 3134
Agendia will be sharing important updates on its Twitter, Facebook and LinkedIn pages throughout the conference. The event program can be found at the ASCO 2022 website.
About Agendia
Agendia is a mission-driven, commercial stage company focused on enabling optimized decision-making by providing physicians with next-generation diagnostic and information solutions that can be used to help improve outcomes for breast cancer patients worldwide. The company currently offers two commercially-available genomic profiling tests that help surgeons, oncologists and pathologists to personalize treatment for women at critical intervention points throughout their patient journey.
MammaPrint® is a 70-gene prognostic test that, along with other clinicopathologic factors, determines a specific patient’s breast cancer recurrence risk. BluePrint® is an 80-gene molecular subtyping test that identifies the underlying biology of an individual breast cancer to provide information about its behavior, long-term prognosis and potential response to systemic therapy. Together, MammaPrint® and BluePrint® provide a holistic view of the biology underlying an individual patient’s breast cancer, enabling physicians to objectively select the best treatment plan.
For more information on Agendia’s assays and ongoing trials, please visit www.agendia.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220502005907/en/
Contact information
Terri Clevenger
Westwicke/ICR Healthcare PR
Tel: 203.856.4326
Terri.Clevenger@icrinc.com
About Business Wire
Business WireSubscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SimCorp Unites with FlexTrade to Add New EMS Ecosystem Partner28.3.2023 09:02:00 CEST | Press release
SimCorp, an independent provider of investment management solutions, has partnered with FlexTrade Systems, a global leader in high-performance multi-asset trade execution management systems (EMS), to extend SimCorp's Order Management System (OMS) capabilities by incorporating the cross-asset EMS functionality of FlexTrade's FlexTRADER EMS. This partnership addresses the increasing demand from trading teams for seamless integration and collaborative workflows between their OMS and EMS solutions. The integration will help optimize trading activities and assist in meeting best execution obligations. As part of the partnership, FlexTrade will join SimCorp's Open Platform program. The Open Platform program is designed to offer its client base frictionless access to innovative fintech solutions across the investment value chain. A key component of the new agreement will see the two firms work together to deliver enhanced, seamless connectivity between SimCorp's OMS, Order Manager, and FlexTr
euNetworks Forms Exclusive Partnership on CrossChannel Fibre System to Deliver Ultra-Low Latency Services Between London and Madrid28.3.2023 09:00:00 CEST | Press release
euNetworks Group Limited (“euNetworks”), a Western European bandwidth infrastructure company, today announced that it has entered into an exclusive partnership agreement with Crosslake Fibre UK Limited (“Crosslake”), an international network provider and developer of unique subsea and terrestrial fibre networks. This partnership relates to Crosslake’s new CrossChannel Fibre system and gives euNetworks exclusivity to deliver ultra-low latency services between the United Kingdom and Madrid on this system to the financial services community. euNetworks has also agreed to a strategic relationship, enabling the sale of dark fibre services by euNetworks using the system. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230328005180/en/ Paula Cogan, CEO of euNetworks (Photo: Business Wire) CrossChannel Fibre is a 550km cable system with end-to-end fibre running between Slough, United Kingdom and Paris, France and is the first subsea
Adva Network Security protects TransnetBW’s communication network28.3.2023 09:00:00 CEST | Press release
Adva Network Security today announced that TransnetBW has deployed its ConnectGuard™ encryption technology with the Adtran FSP 3000 optical transport solution to establish a highly secure communication network in its service area. As the operator of an electricity transmission grid in southwestern Germany and a European interconnection partner, TransnetBW depends on the security and reliability of its communication network to ensure trouble-free operations. That’s why the company chose the FSP 3000 optical platform with Adva Network Security encryption technology, which has been approved by the German Federal Office for Information Security (BSI). This solution enables high-speed connections to be reliably and robustly protected, even against sophisticated cyberattacks. Planning and implementation of the highly secure infrastructure were carried out by Adva Network Security’s long-standing partner Syserso Networks, who will also provide ongoing support. This press release features mult
Fujirebio expands its assay menu in the field of neurodegenerative diseases with the launch of the fully automated Lumipulse ® G NfL CSF and Lumipulse ® G NfL Blood tests28.3.2023 07:00:00 CEST | Press release
H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G NfL CSF and Lumipulse G NfL Blood assays for the fully automated random-access LUMIPULSE® G immunoassay systems. These CLEIA (chemiluminescent enzyme immunoassay) assays allow for the quantitative measurement of Neurofilament light (NfL) in human Cerebrospinal fluid (CSF) and plasma/serum, respectively, within just 35 minutes. The two assays are available for Research Use Only. “In 2022, we introduced three fully automated blood-based assays for the detection of pTau181, β-Amyloid1-42 and β-Amyloid1-40, and we are now proud to once again expand our neurodegenerative disease portfolio with the highly anticipated NfL biomarker,” Christiaan De Wilde, CEO of Fujirebio Europe and Global Head Neuro Business. “The assay menu offered by other industry leaders today is still limited and we are working diligently to create a solid lineup of tests for the entire neurodegenerative
Sofinnova Partners Launches Digital Medicine Strategy28.3.2023 06:00:00 CEST | Press release
Sofinnova Partners (“Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, announced today that it has launched a new investment strategy focused on digital medicine. The strategy will be headed by Partners Edward Kliphuis and Simon Turner, who bring over a decade of experience investing in startups at the intersection of biology, data, and computation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230327005697/en/ Edward Kliphuis (left) and Simon Turner (right) (Photo: Business Wire) Sofinnova Digital Medicine will back entrepreneurs innovating at the cutting edge of technology and biology and help them scale to become global leaders. Like all the funds on Sofinnova’s platform, Sofinnova Digital Medicine will focus on developing the most promising innovations that address systemic challenges in healthcare and can profoundly improve the lives of patients worldwide. Antoine Pap
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom